Could a cancer drug ease arthritis in scleroderma patients?
NCT ID NCT01748084
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether rituximab, a drug used for certain cancers and autoimmune diseases, can reduce joint pain and swelling in people with systemic sclerosis (scleroderma). Twenty-two adults with active arthritis took rituximab or a placebo, plus standard care. Researchers counted tender and swollen joints to see if the drug helped.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab
- What this could lead to
- If it works, this could point toward a treatment for arthritis in people with systemic sclerosis, improving joint pain and quality of life.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. Rituximab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts